PRT-3645

N/A

Report date: 2022/12/03 23:07:51
NME

Base Information

Drug NamePRT-3645
Drug Alias NamePRT-3645
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 4 inhibitorsCyclin-dependent kinase 6 inhibitors
TargetsCyclin-dependent kinase 4Cyclin-dependent kinase 6
Therapy Area/IndicationsBrain metastasesEndometrial NeoplasmsCarcinoma, Non-Small-Cell Lung +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingapore
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesPrelude Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesPrelude Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsBrain metastasesEndometrial NeoplasmsCarcinoma, Non-Small-Cell Lung +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A